Showing results (1321-1330 of 1,380) with videos related to
Sort By:
Pageof 138
Nature|February 7, 2020
The repertoire of mutational signatures in human cancerLudmil B Alexandrov, Jaegil Kim, Nicholas J Haradhvala, et al.Science (New York, N.Y.)|September 28, 2023
Ethically cleared to launch?Vasiliki Rahimzadeh, Jennifer Fogarty, Timothy Caulfield, et al.Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.Alimentary Pharmacology & Therapeutics|October 18, 2024
Faecal Volatile Organic Compounds to Detect Colorectal Neoplasia in Lynch Syndrome-A Prospective Longitudinal Multicentre StudyElsa L S A van Liere, Dewkoemar Ramsoekh, Emma Daulton, et al.Bioorganic & Medicinal Chemistry Letters|May 10, 2022
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approachColin Zhang, Meizhong Xu, Chunhong He, et al.Journal of Medicinal Chemistry|May 27, 2026
Discovery of Dual A2A/A2B Adenosine Receptor Antagonist and Clinical Candidate INCB106385Chao Qi, Matthew S McCammant, Yong Li, et al.Journal of Medicinal Chemistry|November 10, 2022
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3Artem Shvartsbart, Jeremy J Roach, Michael R Witten, et al.Bioorganic & Medicinal Chemistry Letters|February 8, 2011
Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonistChangsheng Zheng, Ganfeng Cao, Michael Xia, et al.Proceedings of the National Academy of Sciences of the United States of America|June 28, 2013
Comparative transcriptomics reveals patterns of selection in domesticated and wild tomatoDaniel Koenig, José M Jiménez-Gómez, Seisuke Kimura, et al.Journal of the American Academy of Dermatology|April 29, 2020
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinomaAshley Wysong, Jason G Newman, Kyle R Covington, et al.Pageof 138